Koninklijke Philips N.v. · EURONEXT:PHIA
Koninklijke Philips — Koninklijke Philips N.V. NY Registry Shares — Q2 2025 Earnings Presentation
26 slides from Koninklijke Philips's earnings presentation, Jul 29, 2025
Slide 1: Q2 2025 Group Highlights
Quarterly report Q2 2025 Philips builds strong order intake momentum and drives margin expansion in Q2 Amsterdam, July 29, 2025 Q2 2025 Group Highlights • Comparable order intake growth 6% • Group sales EUR 4.3 billion, reflecting 1% increase in comparable sales • Income from operations EUR 400 mill
Slide 2: Innovation highlights, Productivity and Outlook
Innovation highlights • Philips signed a long-term partnership with Indonesia’s Ministry of Health to deliver nationwide coverage of its advanced Azurion image-guided therapy system, expanding access to cardiac, stroke and cancer care to more than 280 million people across all 38 provinces. • Philip
Slide 3: Philips performance
Philips performance Key data in millions of EUR unless otherwise stated* Q2 2024 Q2 2025 • Comparable sales increased by 1%. The 6% growth in Personal Sales 4,462 4,338 Health was offset by a 1% decline both in Connected Care and Nominal sales growth 0% (3%) Diagnosis & Treatment, on the back of a h
Slide 4: Performance per segment
Performance per segment Diagnosis & Treatment Key data in millions of EUR unless otherwise stated* Q2 2024 Q2 2025 • Comparable sales decreased by 1%, with growth in Image Guided Sales 2,174 2,084 Therapy offset by a low-single-digit decline in Precision Diagnosis, on Nominal sales growth 3% (4%) th
Slide 5: Philips semi-annual report 2025
Philips semi-annual report 2025 Introduction This report contains the semi-annual report of Koninklijke Philips N.V. (‘the Company’ or ‘Philips’), a company with limited liability, headquartered in Amsterdam, the Netherlands. The principal activities of the Company and its group companies (‘the Grou
Slide 6: Management report Philips performance
Management report Philips performance Key data in millions of EUR unless otherwise stated January to June • Comparable sales decreased by 1%, including a decline in China. 2024 2025 Mid-single-digit growth in Personal Health was offset by low-single- Sales 8,600 8,434 digit declines in Diagnosis & T
Slide 7: Performance per segment
Performance per segment Diagnosis & Treatment Key data in millions of EUR unless otherwise stated January to June • Comparable sales decreased by 3% on the back of mid-single-digit 2024 2025 growth in the first half of 2024. Growth in Image Guided Therapy Sales 4,200 4,048 was more than offset by a
Slide 8: Other
Other Key data in millions of EUR unless otherwise stated January to June • Sales decreased by EUR 19 million, mainly driven by lower royalty 2024 2025 income. Sales 279 260 • Adjusted EBITA increased by EUR 21 million, mainly driven by lower Income from operations (94) (48) costs. EBITA ¹ (88) (42)
Slide 9: Forward-looking statements and other information
Forward-looking statements and other information Forward-looking statements Market Abuse Regulation This document and the related oral presentation, including responses This press release contains inside information within the meaning of to questions following the presentation, contain certain forwa
Slide 10: Condensed consolidated statements of income
Condensed consolidated statements of income In millions of EUR unless otherwise stated* Q2 January to June 2024 2025 2024 2025 Sales 4,462 4,338 8,600 8,434 Cost of sales (2,473) (2,327) (4,796) (4,575) Gross margin 1,989 2,011 3,804 3,859 Selling expenses (1,127) (1,084) (2,223) (2,171) General and
Slide 11: Condensed consolidated statements of comprehensive income
Condensed consolidated statements of comprehensive income in millions of EUR* Q2 January to June 2024 2025 2024 2025 Net income for the period 452 240 (546) 312 Pensions and other post-employment plans: Remeasurement, before tax - - - 1 Income tax effect on remeasurements 1 1 4 3 Financial assets fa
Slide 12: Condensed consolidated balance sheets
Condensed consolidated balance sheets in millions of EUR* December 31, 2024 June 30, 2025 Non-current assets: Property, plant and equipment 2,452 2,260 Goodwill 10,383 9,363 Intangible assets excluding goodwill 2,982 2,712 Non-current receivables 208 250 Investments in associates 257 224 Other non-c
Slide 13: Condensed consolidated statements of cash flows
Condensed consolidated statements of cash flows in millions of EUR* Q2 January to June 2024 2025 2024 2025 Cash flows from operating activities: Net income (loss) 452 240 (546) 312 Results of discontinued operations - net of income tax (141) 2 (142) 8 Adjustments to reconcile net income to net cash
Slide 14: Condensed consolidated statements of changes in equity
Condensed consolidated statements of changes in equity in millions of EUR* Common Capital in Fair value Cash flow Currency Retained Treasury Total Non- Group shares excess of through hedges translation earnings shares at shareholders’ controlling equity par value OCI differences cost equity interest
Slide 15: Notes to the unaudited semi-annual condensed consolidated financial statements
Notes to the unaudited semi-annual condensed consolidated financial statements Basis of preparation development of local regulations and compliance thereto. Philips These condensed consolidated financial statements for the six-month observes this trend in the major markets in which it operates and h
Slide 16: Segment information
Segment information Philips’ operating segments are Diagnosis & Treatment, Connected Care and Personal Health, each being responsible for the management of its business worldwide. Sales and Adjusted EBITA 1 in millions of EUR unless otherwise stated January to June 2024 2025 Sales incl. Sales incl.
Slide 17: Other business income and expenses, Income taxes, Goodwill
Sales and tangible and intangible assets in millions of EUR Sales Tangible and intangible assets ¹ January to June December 31, June 30, 2024 2025 2024 2025 Netherlands 1,103 1,126 1,662 1,605 United States 3,479 3,476 11,607 10,282 China 651 579 250 216 Japan 465 469 396 388 Germany 303 297 392 415
Slide 18: Divestment, Subsequent events, Fair value of financial assets and liabilities
Respironics field action provision registration process for the personal injury settlement and subsequently On June 14, 2021, Philips’ subsidiary Philips RS North America LLC the settlement amounts have been fully paid in the first half of 2025. (Philips Respironics) issued a voluntary recall notifi
Slide 19: Fair value of financial assets and liabilities
Fair value of financial assets and liabilities in millions of EUR December 31, 2024 June 30, 2025 Carrying Estimated Carrying Estimated amount fair value ¹ amount fair value ¹ Level 1 Level 2 Level 3 Financial assets Carried at fair value: Debt instruments 231 231 218 218 218 Equity instruments 3 3
Slide 20: Reconciliation of non-IFRS information
Reconciliation of non-IFRS information Certain non-IFRS financial measures are presented when discussing the Philips Group’s performance: For the definitions of the non-IFRS financial measures listed above, refer • Comparable sales growth to chapter 9.9, Reconciliation of non-IFRS information, of th
Slide 21: Reconciliation of Net income to Adjusted EBITA and Adjusted EBITDA Q2 2025
Reconciliation of Net income to Adjusted EBITA and Adjusted EBITDA in millions of EUR Diagnosis & Philips Group Treatment Connected Care Personal Health Other Q2 2025 Net income 240 Discontinued operations, net of income taxes 2 Income tax expense (benefit) 95 Investments in associates, net of incom
Slide 22: Reconciliation of Net income to Adjusted EBITA and Adjusted EBITDA Q2 2024
Diagnosis & Philips Group Treatment Connected Care Personal Health Other Q2 2024 Net income 452 Discontinued operations, net of income taxes (141) Income tax expense (benefit) 345 Investments in associates, net of income taxes 93 Financial expenses 88 Financial income (20) Income from operations 816
Slide 23: Composition of free cash flow
Composition of free cash flow in millions of EUR Q2 January to June 2024 2025 2024 2025 Net cash flows from operating activities 89 387 (82) (546) Net capital expenditures (153) (156) (318) (315) Purchase of intangible assets (28) (24) (64) (70) Expenditures on development assets (55) (72) (108) (13
Slide 24: Philips statistics
Philips statistics Quarterly statistics in millions of EUR unless otherwise stated 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Sales 4,138 4,462 4,377 5,044 4,097 4,338 Nominal sales growth (1%) 0% (2%) 0% (1%) (3%) Comparable sales growth ¹ 2% 2% 0% 1% (2%) 1% Comparable order intake ² (4%) 9% (2%) 2% 2% 6%
Slide 25: Year-to-date statistics
Year-to-date statistics in millions of EUR unless otherwise stated 2024 2025 January- January- January- January- January- January- January- January- March June September December March June September December Sales 4,138 8,600 12,977 18,021 4,097 8,434 Nominal sales growth (1%) 0% (1%) (1%) (1%) (2%
Slide 26: © 2025 Koninklijke Philips N.V. All rights reserved.
© 2025 Koninklijke Philips N.V. All rights reserved. https://www.philips.com/investorrelations
Koninklijke Philips N.V. NY Registry Shares — Q2 2025 Earnings Presentation on 6ix